Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_assertion description "[We proposed that the remarkable efficacy and broad spectrum of RLIP76-targeted therapy is because its glutathione-conjugate (GS-E) transport activity is required for clathrin-dependent endocytosis (CDE), which regulates all ligand-receptor signaling, and that RLIP76 is required not only for survival of cancer cells but also for their very existence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_assertion evidence source_evidence_literature NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_assertion SIO_000772 21220488 NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_assertion wasDerivedFrom befree-20150227 NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_assertion wasGeneratedBy ECO_0000203 NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.
- befree-20150227 importedOn "2015-02-27" NP856250.RA0_hA-8S5vLvs5iyMwVcGrF8qQDXhS_RGUVjOLhIuHpw130_provenance.